References
- Almquist LM, Karagas MR, Christensen BC et al (2011). The role of TP53 and MDM2 polymorphisms in TP53 mutagenesis and risk of non-melanoma skin cancer. Carcinogenesis, 32, 327-30. https://doi.org/10.1093/carcin/bgq256
- Ambrosini G, Sambol EB, Carvajal D et al (2007). Mouse double minute antagonist Nutlin-3a enhances chemotherapyinduced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene, 26, 3473-81. https://doi.org/10.1038/sj.onc.1210136
- Azmi AS, Philip PA, Aboukameel A et al (2010). Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy. Curr Cancer Drug Targets, 10, 319-31. https://doi.org/10.2174/156800910791190229
- Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G (1993). Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev, 7, 812-21. https://doi.org/10.1101/gad.7.5.812
- Blaydes JP, Wynford-Thomas D (1998). The proliferation of normal human fibroblasts is dependent upon negative regulation of p53 function by mdm2. Oncogene, 16, 3317-22. https://doi.org/10.1038/sj.onc.1201880
- Bond GL, Hu W, Bond EE et al (2004). A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 119, 591-602. https://doi.org/10.1016/j.cell.2004.11.022
- Burton EC, Lamborn KR, Forsyth P et al (2002). Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Clin Cancer Res, 8, 180-7.
- Chen H, Zhang D, Wu J et al (2014). Ubiquitination of p53 is involved in troglitazone induced apoptosis in cervical cancer cells. Asian Pac J Cancer Prev, 15, 2313-8. https://doi.org/10.7314/APJCP.2014.15.5.2313
- Cheng H, Ma B, Jiang R et al (2012). Individual and combined effects of MDM2 SNP309 and TP53 Arg72Pro on breast cancer risk: an updated meta-analysis. Mol Biol Rep, 39, 9265-74. https://doi.org/10.1007/s11033-012-1800-z
- Del SG, Murphy M, Ruaro E et al (1996). Cyclin D1 and p21/waf1 are both involved in p53 growth suppression. Oncogene, 12, 177-85.
- Dharel N, Kato N, Muroyama R et al (2006). MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res, 12, 4867-71. https://doi.org/10.1158/1078-0432.CCR-06-0111
- Dong HJ, Fang C, Fan L et al (2012). MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL. Int J Cancer, 130, 2054-61. https://doi.org/10.1002/ijc.26222
- Evan GI, Vousden KH (2001). Proliferation, cell cycle and apoptosis in cancer. Nature, 411, 342-8. https://doi.org/10.1038/35077213
- Fearon ER (1997). Human cancer syndromes: clues to the origin and nature of cancer. Science, 278, 1043-50. https://doi.org/10.1126/science.278.5340.1043
- Francoz S, Froment P, Bogaerts S et al (2006). Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci USA, 103, 3232-7. https://doi.org/10.1073/pnas.0508476103
- Frazer KA, Murray SS, Schork NJ, Topol EJ (2009). Human genetic variation and its contribution to complex traits. Nat Rev Genet, 10, 241-51.
- Frietze S, Lupien M, Silver PA, Brown M (2008). CARM1 regulates estrogen-stimulated breast cancer growth through up-regulation of E2F1. Cancer Res, 68, 301-6. https://doi.org/10.1158/0008-5472.CAN-07-1983
- Grinstein E, Jundt F, Weinert I, Wernet P, Royer HD (2002). Sp1 as G1 cell cycle phase specific transcription factor in epithelial cells. Oncogene, 21, 1485-92. https://doi.org/10.1038/sj.onc.1205211
- Guan Y, Yang X, Yao G et al (2014). Breast cancer association studies in a Han Chinese population using 10 Europeanancestry-associated breast cancer susceptibility SNPs. Asian Pac J Cancer Prev, 15, 85-91. https://doi.org/10.7314/APJCP.2014.15.1.85
- Hitzenbichler F, Stoehr CG, Rogenhofer M et al (2013). Mdm2 SNP309 G-variant is associated with invasive growth of human urinary bladder cancer. Pathobiology, 81, 53-9.
- Hori M, Shimazaki J, Inagawa S, Itabashi M, Hori M (2002). Overexpression of MDM2 oncoprotein correlates with possession of estrogen receptor alpha and lack of MDM2 mRNA splice variants in human breast cancer. Breast Cancer Res Treat, 71, 77-83. https://doi.org/10.1023/A:1013350419426
- Hu Z, Jin G, Wang L, Chen F, Wang X, Shen H (2007). MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol Biomarkers Prev, 16, 2717-23. https://doi.org/10.1158/1055-9965.EPI-07-0634
- Jones SN, Roe AE, Donehower LA, Bradley A (1995). Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature, 378, 206-8. https://doi.org/10.1038/378206a0
- Jung JK, Arora P, Pagano JS, Jang KL (2007). Expression of DNA methyltransferase 1 is activated by hepatitis B virus X protein via a regulatory circuit involving the p16INK4acyclin D1-CDK 4/6-pRb-E2F1 pathway. Cancer Res, 67, 5771-8. https://doi.org/10.1158/0008-5472.CAN-07-0529
- Kowalik TF, DeGregori J, Leone G, Jakoi L, Nevins JR (1998). E2F1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2. Cell Growth Differ, 9, 113-8.
- Leach FS, Tokino T, Meltzer P et al (1993). p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res, 53, 2231-34.
- Li LB, Louie MC, Chen HW, Zou JX (2008). Proto-oncogene ACTR/AIB1 promotes cancer cell invasion by up-regulating specific matrix metalloproteinase expression. Cancer Lett, 261, 64-73. https://doi.org/10.1016/j.canlet.2007.11.013
- Liu K, Luo Y, Tian H et al (2014). The tumor suppressor LKB1 antagonizes WNT signaling pathway through modulating GSK3beta activity in cell growth of esophageal carcinoma. Tumor Biol, 35, 995-1002. https://doi.org/10.1007/s13277-013-1133-0
- Louie MC, Zou JX, Rabinovich A, Chen HW (2004). ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance. Mol Cell Biol, 24, 5157-71. https://doi.org/10.1128/MCB.24.12.5157-5171.2004
- Lukas J, Pagano M, Staskova Z, Draetta G, Bartek J (1994). Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumour cell lines. Oncogene, 9, 707-18.
- Luo H, Li Z, Qing Y et al (2014). Single nucleotide Polymorphisms of DNA base-excision repair genes (APE1, OGG1 and XRCC1) associated with breast cancer risk in a Chinese population. Asian Pac J Cancer Prev, 15, 1133-40. https://doi.org/10.7314/APJCP.2014.15.3.1133
- Martin K, Trouche D, Hagemeier C et al (1995). Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature, 375, 691-4. https://doi.org/10.1038/375691a0
- Mendrysa SM, McElwee MK, Michalowski J et al (2003). mdm2 Is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol, 23, 462-72. https://doi.org/10.1128/MCB.23.2.462-473.2003
- Michael D, Oren M (2003). The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol, 13, 49-58. https://doi.org/10.1016/S1044-579X(02)00099-8
- Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B (1992). Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature, 358, 80-3. https://doi.org/10.1038/358080a0
- Olsson H, Hultman P, Rosell J, Soderkvist P, Jahnson S (2013). MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1. BMC Urol, 13, 5. https://doi.org/10.1186/1471-2490-13-5
- Onat OE, Tez M, Ozcelik T, Toruner GA (2006). MDM2 T309G polymorphism is associated with bladder cancer. Anticancer Res, 26, 3473-5.
- Petrocca F, Visone R, Onelli MR, et al (2008). E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell, 13, 272-86. https://doi.org/10.1016/j.ccr.2008.02.013
- Schiebe M, Ohneseit P, Hoffmann W et al (2000). Analysis of mdm2 and p53 gene alterations in glioblastomas and its correlation with clinical factors. J Neurooncol, 49, 197-203. https://doi.org/10.1023/A:1006410702284
- Shangary S, Wang S (2009). Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol, 49, 223-41. https://doi.org/10.1146/annurev.pharmtox.48.113006.094723
- Shinohara A, Sakano S, Hinoda Y et al (2009). Association of TP53 and MDM2 polymorphisms with survival in bladder cancer patients treated with chemoradiotherapy. Cancer Sci, 100, 2376-82. https://doi.org/10.1111/j.1349-7006.2009.01331.x
- Song H, Li Z, Deng X, et al (2014). Expression of bcl-2 and p53 in induction of esophageal cancer cell apoptosis by ECRG2 in combination with cisplatin. Asian Pac J Cancer Prev, 15, 1397-401. https://doi.org/10.7314/APJCP.2014.15.3.1397
- Stacey DW (2003). Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr Opin Cell Biol, 15, 158-63. https://doi.org/10.1016/S0955-0674(03)00008-5
- Stender JD, Frasor J, Komm B et al (2007). Estrogen-regulated gene networks in human breast cancer cells: involvement of E2F1 in the regulation of cell proliferation. Mol Endocrinol, 21, 2112-23. https://doi.org/10.1210/me.2006-0474
- Su L, Li X, Gao X, et al (2014). Cytogenetic and genetic mutation features of de novo acute myeloid leukemia in elderly Chinese patients. Asian Pac J Cancer Prev, 15, 895-8. https://doi.org/10.7314/APJCP.2014.15.2.895
- Tuna B, Yorukoglu K, Tuzel E et al (2003). Expression of p53 and mdm2 and their significance in recurrence of superficial bladder cancer. Pathol Res Pract, 199, 323-8. https://doi.org/10.1078/0344-0338-00424
- Vassilev LT (2007). MDM2 inhibitors for cancer therapy. Trends Mol Med, 13, 23-31. https://doi.org/10.1016/j.molmed.2006.11.002
- Willander K, Ungerback J, Karlsson K et al (2010). MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia. Eur J Haematol, 85, 251-6. https://doi.org/10.1111/j.1600-0609.2010.01470.x
- Xiong J, Yang Q, Li J, Zhou S (2014). Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer. Angiogenesis, 17, 35-50.
- Zawlik I, Kita D, Vaccarella S et al (2009). Common polymorphisms in the MDM2 and TP53 genes and the relationship between TP53 mutations and patient outcomes in glioblastomas. Brain Pathol, 19, 188-94. https://doi.org/10.1111/j.1750-3639.2008.00170.x
- Zeichner S, Alghamdi S, Elhammady G, Poppiti, R (2014). Prognostic Significance of TP53 Mutations and Single Nucleotide Polymorphisms in Acute Myeloid Leukemia:A case Series and Literature Review. Asian Pac J Cancer Prev, 15, 1603-9. https://doi.org/10.7314/APJCP.2014.15.4.1603
- Zhang Z, Li M, Wang H, Agrawal S, Zhang R (2003). Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci USA, 100, 11636-41. https://doi.org/10.1073/pnas.1934692100
- Zhang Z, Wang H, Li M et al (2005). Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene, 24, 7238-47. https://doi.org/10.1038/sj.onc.1208814
- Zhao E, Cui D, Yuan L, Lu W (2012). MDM2 SNP309 polymorphism and breast cancer risk: a meta-analysis. Mol Biol Rep, 39, 3471-7. https://doi.org/10.1007/s11033-011-1119-1
- Zhou G, Zhai Y, Cui Y et al. (2007). MDM2 promoter SNP309 is associated with risk of occurrence and advanced lymph node metastasis of nasopharyngeal carcinoma in Chinese population. Clin Cancer Res, 13, 2627-33. https://doi.org/10.1158/1078-0432.CCR-06-2281
Cited by
- Identification of High Affinity Non-Peptidic Small Molecule Inhibitors of MDM2-p53 Interactions through Structure-Based Virtual Screening Strategies vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3759
- TRIP12 as a mediator of human papillomavirus/p16-related radiation enhancement effects vol.36, pp.6, 2017, https://doi.org/10.1038/onc.2016.250
- Exogenous C8-Ceramide Induces Apoptosis by Overproduction of ROS and the Switch of Superoxide Dismutases SOD1 to SOD2 in Human Lung Cancer Cells vol.19, pp.10, 2018, https://doi.org/10.3390/ijms19103010